melanoma
Five facts about UV exposure and sun safety
July 7, 2025Medical Communications Dermatology, Five Facts, Oncology, Skin, melanoma, skincare
1We can acclimatise to UV exposure. For example, we’re more likely to burn if there’s a sunny spell earlier in …
INDEPENDENT PARSORTIX STUDY HIGHLIGHTS BENEFITS OF COMBINED DNA ANALYSIS IN MELANOMA
August 1, 2024Medical Communications, Research and Development Angle, Internal Medicine, Oncology, Parsortix, melanoma
Multi-analyte approach has potential to guide personalised cancer care CTC mutation profiles associated with more aggressive disease ANGLE plc. a …
Iovance’s Amtagvi gains FDA accelerated approval for melanoma treatment
February 19, 2024Medical Communications Iovance, Oncology, accelerated approval, melanoma
Iovance Biotherapeutics has announced that the US Food and Drug Administration (FDA) has approved Amtagvi (lifileucel) suspension for intravenous infusion …
Elekta and BMS partner for digital treatment for melanoma
December 19, 2023Research and Development BMS, Elekta, Oncology, bristol myers squibb, digital treatment, melanoma
Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan to develop a digital solution …
Melanoma market to reach $7.4bn by 2029
April 30, 2021Medical Communications melanoma
A report from GlobalData, Melanoma – Global Drug Forecast and Market Analysis to 2029, has predicted the melanoma industry will …
Novartis’ Tafinlar/Mekinist combo improves five-year relapse-free survival in new Phase 3 data
September 17, 2020Research and Development Novartis, Tafinlar, mekinist, melanoma
Novartis has unveiled promising new Phase 3 data for its combination of Tafinlar (dabrafenib) with Mekinist (trametinib) in the treatment …
Scotland approves targetted combination therapy for advanced melanoma
February 11, 2020Manufacturing and Production NHS, SMC, Scotland, UK, advanced melanoma, melanoma
The Scottish Medicines Consortium (SMC) has approved targeted combination therapy for the treatment of adult patient with unresectable or metastatic …
Roche’s Tecentriq combo boosts progression-free survival in previously untreated BRAF V600 mutation-positive advanced melanoma
December 16, 2019Manufacturing and Production, Research and Development, Sales and Marketing Roche, melanoma, pharma, tecentriq
Roche has lifted the curtain on new Phase 3 data for its immunotherapy Tecentriq (atezolizumab), confirming that the therapy, when …
EMA’s CHMP recommends new dosing schedule for Opdivo in melanoma
September 25, 2019Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, CHMP, EMA, melanoma, opdivo, pharma
Bristol-Myers Squibb has revealed that its blockbuster immunotherapy drug Opdivo (nivolumab) has secured recommendation from the EMA’s Committee for Medicinal …
MSD’s Keytruda recommended on NHS in Scotland for Stage 3 melanoma
May 14, 2019Manufacturing and Production, Sales and Marketing Cancer, MSD, Scotland, Scottish Medicines Consortium, keytruda, melanoma, pharma
MSD has revealed that Keytruda (pembrolizumab) will be made available to NHS Scotland patients after the Scottish Medicines Consortium (SMC) …
Living with melanoma after surgery
February 25, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, melanoma, patient experience, pharma
Dr Elizabeth Walmsley was left lost when she received her melanoma diagnosis. Thankfully, through perseverance and the advice of friends …
Smoking may limit immune system’s ability to fight cancer, study shows
February 18, 2019Sales and Marketing Cancer, cancer research, immune system, immunology, melanoma, oncology, smoking
Smoking may limit the body’s ability to fight melanoma, according to a study published in the journal Cancer Research. The …
NICE recommends Pierre Fabre’s Braftovi in BRAF V600-mutated advanced melanoma
January 21, 2019Sales and Marketing Braftovi, Cancer, NICE, Pierre Fabre, UK, melanoma, pharma
Braftovi (encorafenib), a BRAF kinase inhibitor developed by Pierre Fabre, has been awarded approval in combination with Mektovi (binimetinib) by …
Opdivo to be made available to UK melanoma patients via the Cancer Drugs Fund
November 30, 2018Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Cancer Drugs Fund, NICE, UK, melanoma, pharma
Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) is set to be made available to patients in the UK via the Cancer …
MSD’s Keytruda to treat melanoma in England on the Cancer Drugs Fund
November 19, 2018Sales and Marketing England, MSD, NHS, UK, keytruda, melanoma, pharma
MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) will now be made available to patients in England via the Cancer Drugs Fund, it …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
